| 1. Expression profiles of miRNAs in sera of PDAC patients and the expression and function of hsa-miR-125a-5p in PDAC.Pancreatic ductal adenocarcinoma(PDAC) is an aggressive digestive malignancy with poor prognosis, and its5-year survival rate is about6%. The high mortality rate for pancreatic cancer is primarily due to difficulty of early detection and its diagnosis could be done almost at advanced stage. Therefore, it’s urgent to find a kind of biomarker that is effective for early detection of PDAC.MicroRNAs (miRNAs) are a class of endogenous small non-coding RNAs, which are single-stranded and consist of18-25nucleotides. Recently, it was reported that miRNAs could stably exist in sera, with its expression profile changing in accordance with the pathological conditions, and may become the potential detection and therapeutic targets of diseases. In this study, we used TaqMan MicroRNA Open Array technique to screen the differentially expressed miRNAsin sera.As a result,20up-regulated and63down-regulated miRNAs were detected between PDAC patients sera and healthy people sera. Combined with the data of PDAC tissue microarray, we determined to investigate the mechanism of hsa-miR-125a-5p in PDAC carcinogenesis. We found hsa-miR-125a-5p was significantly highly expressed in PDAC tissues and cell lines compared to normal pancreas.The growth ability, colony formation and cell cycle of PDAC cell lines Panc-1and MIA PaCa-2were suppressed by transfection with the hsa-miR-125a-5p inhibitor. These data indicated that hsa-miR-125a-5p may play an oncogenic role in PDAC, suggesting the potential for hsa-miR-125a-5p to be used as a target of early diagnosis biomarker and treatment of PDAC.2. Study on the expression of a novel biomarker HAb18G/CD147in pancreatic neuroendocrine neoplasmsPancreaticneuroendocrine neoplasms(PNENs) account for1%to2%of all pancreatic tumors. The inspecting methods used for PNENs include serology, imaging and so on, among which, pathological diagnosis is the unique method to make a definite diagnosis for PNENs. Pathological diagnosis depends on morphology and immunohistochemistry(IHC). The antibodies used in IHC include neuroendocrine markers as well as various functional peptide hormones. However, these antibodies only help to define neuroendocrine nature of tumors and function of state, they cannot indicate the severity and prognosis of this disease. The methods for histological grading, which could indicate the severity and prognosis of this disease, are complicated and time-consuming. So it is urgent to find a new marker which is positively expressed in PNENs and could be easily interpreted. HAb18G/CD147, a member of immunoglobulin super family, is a kind of transmembrane glycoprotein newly found. It has been found to be highly expressed in most of cancer tissues, while expressed negatively or at a very low level in normal tissues. It has been proved to be an independent predictor of poor prognosis of tumors and it’s role in tumor growth, invasion and metastasis has become a research hotspot at present. We found HAb18G/CD147washighly expressed in PNENs tissues, whereas negative in normal islets. The immunophenotypes of HAb18G/CD147in PNENs could display as cytoplasm, membrane and membrane-cytoplasm, and the latter two immunophenotypes may indicate poor differentiation of this disease. The expression level of HAb18G/CD147in PNENs was positively correlated with tumor size, histological grade, metastasis and TNM stage. HAb18G/CD147may provide new ideas in diagnosis of PNENs as an indicator to assess the severity and prognosis of this disease, and has potential clinical application value. |
PDF Full Text Request